De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients

Figure 2

Risk of developing late antibody-mediated rejection (AMR), renal function decline, and graft loss, in the 39 patients who developed de novo donor-specific antibodies (dnDSAs), according to the time to HLA-antibody occurrence. (a) AMR-free allograft survival in kidney graft recipients, stratified by early or late development of dnDSAs; (b) renal graft function decline (eGFR ≤ 50 ml/min/1.73 m²) in kidney graft recipients, stratified by early or late development of dnDSAs; (c) allograft survival in kidney graft recipients, stratified by early or late development of dnDSAs. The statistical difference between Kaplan-Meier survival curves was evaluated by the log-rank test and differences with values < 0.05 were considered statistically significant.

(a)

(b)

(c)